Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study

NCT05835219 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT05835219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
June 19, 2023
Completion date
August 29, 2025
Enrollment
145 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

recurrence of clostridium difficile infection